Related references
Note: Only part of the references are listed.Antibodies to the CD5 molecule in normal human immunoglobulins for therapeutic use (intravenous immunoglobulins, IVIg)
T. VASSILEV et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2010)
Inflammatory muscle diseases: a critical review on pathogenesis and therapies
Marinos C. Dalakas
CURRENT OPINION IN PHARMACOLOGY (2010)
Structure and function of immunoglobulins
Harry W. Schroeder et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2010)
Intravenous immunoglobulins - understanding properties and mechanisms
A. Durandy et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2009)
CONSENSUS STATEMENT: THE USE OF INTRAVENOUS IMMUNOGLOBULIN IN THE TREATMENT OF NEUROMUSCULAR CONDITIONS REPORT OF THE AANEM AD HOC COMMITTEE
Peter D. Donofrio et al.
MUSCLE & NERVE (2009)
EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases
I. Elovaara et al.
EUROPEAN JOURNAL OF NEUROLOGY (2008)
Proposed immunologic models of the inflammatory myopathies and potential therapeutic implications
Steven A. Greenberg
NEUROLOGY (2007)
Intravenous immunoglobulins suppress T-cell priming by modulating the bidirectional interaction between dendritic cells and natural killer cells
Thanyalak Tha-In et al.
BLOOD (2007)
Successful treatment of dermatomyositis during pregnancy with intravenous immunoglobulin monotherapy
Lloyd Williams et al.
OBSTETRICS AND GYNECOLOGY (2007)
Therapeutic options in autoimmune inflammatory myopathies (dermatomyositis, polymyositis, inclusion body myositis)
Dieter Pongratz
JOURNAL OF NEUROLOGY (2006)
Intravenous immunoglobulin in autoimmune disorders: An insight into the immunoregulatory mechanisms
J Bayry et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2006)
Serum levels of matrix metalloproteinases-2 and-9 and their tissue inhibitors in inflammatory neuromuscular disorders
S. Hurnaus et al.
EUROPEAN NEUROLOGY (2006)
Gene expression profile in the muscles of patients with inflammatory myopathies: effect of therapy with IVIg and biological validation of clinically relevant genes
R Raju et al.
BRAIN (2005)
Matrix metalloproteinases and skeletal muscle: A brief review
E Carmeli et al.
MUSCLE & NERVE (2004)
Intravenous immunoglobulin in autoimmune neuromuscular diseases
MC Dalakas
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2004)
Polymyositis and dermatomyositis
MC Dalakas et al.
LANCET (2003)
Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin
J Bayry et al.
BLOOD (2003)
Results and long-term followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis - An open study with thirty-five adult patients
P Cherin et al.
ARTHRITIS AND RHEUMATISM (2002)
Cyclosporin A and intravenous immunoglobulin treatment in polymyositis/dermatomyositis
MG Danieli et al.
ANNALS OF THE RHEUMATIC DISEASES (2002)
FcγRIIB as a potential molecular target for intravenous gamma globulin therapy
VL Ott et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2001)
Advances in immunology: Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin.
MD Kazatchkine et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Intravenous gammaglobulins in refractory polymyositis: lower dose for maintenance treatment is effective
S Genevay et al.
ANNALS OF THE RHEUMATIC DISEASES (2001)
A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM
MC Dalakas et al.
NEUROLOGY (2001)
Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor
A Samuelsson et al.
SCIENCE (2001)
Downregulation of TGF-β1 mRNA and protein in the muscles of patients with inflammatory myopathies after treatment with high-dose intravenous immunoglobulin
K Amemiya et al.
CLINICAL IMMUNOLOGY (2000)
Expression of matrix metalloproteinases in the muscle of patients with inflammatory myopathies
YC Choi et al.
NEUROLOGY (2000)
High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study
MC Walter et al.
JOURNAL OF NEUROLOGY (2000)